Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Japan could offer unapproved Ebola drug

Published 25/08/2014, 08:23
Japan could offer unapproved Ebola drug
4901
-

TOKYO (Reuters) - Japan would like to offer a drug to help treat the deadly Ebola virus before the World Health Organization officially rules on its use, the country's top government spokesman said on Monday.

Chief Cabinet Secretary Yoshihide Suga told a news conference that Japan has received inquiries from some countries on the influenza drug favipiravir, or T-705 as it is known in the developmental code.

"I am informed that medical professionals could make a request for T-705 in an emergency even before a decision (on approval) by the WHO. In that case, we would like to respond under certain criteria," he said.

Japan's Fujifilm Holdings Corp and U.S. partner MediVector are in talks with the U.S. Food and Drug Administration to submit an application to expand the use of favipiravir as a treatment for Ebola.

Following Suga's comments, Fujifilm shares rose 4.0 percent, edging near a four-year peak hit earlier this month. They were the eighth most actively traded shares on the Tokyo Stock Exchange's main board.

© Reuters. People living outside the Ebola quarantine area of Westpoint walk at a checkpoint while carrying food and essentials for their relatives in quarantine, in Monrovia

The Ebola epidemic in West Africa has killed more than 1,000 people and prompted the WHO to declare an international health emergency.

(Reporting by Kaori Kaneko and Tomo Uetake; Editing by Chris Gallagher and Jeremy Laurence)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.